# In-depth Genetic and Molecular Characterization of Unilateral Coexisting Adrenal Cortical Adenoma and Carcinoma in the Context of MEN1 Syndrome

**Authors:** Francesca Cioppi, Tommaso Orioli, Giulia Cantini, Tonino Ercolino, Federica Cioppi, Guillaume Assié, Anne Jouinot, Anna Aurora Dedonno, Raffaella Santi, Ronald R. de Krijger, Mario Maggi, Matteo Benelli, Letizia Canu, Gabriella Nesi, Michaela Luconi

PMC · DOI: 10.1007/s12022-026-09908-0 · 2026-03-10

## TL;DR

This study explores the genetic differences between benign and malignant adrenal tumors in a patient with MEN1 syndrome, suggesting a possible but not proven link between them.

## Contribution

The study provides a detailed genetic comparison of coexisting benign and malignant adrenal tumors in a MEN1 patient, offering insights into their potential relationship.

## Key findings

- MEN1 loss of heterozygosity was found in the carcinoma but not the adenoma.
- Shared variants between benign and malignant tumors suggest a possible genetic link.
- Clonal evolution analysis revealed distinct mutations in the carcinoma and recurrence.

## Abstract

Adrenal lesions often occur in patients with multiple endocrine neoplasia type 1 (MEN1), mostly adrenal cortical adenomas (ACAs), although the frequency of adrenal cortical carcinomas (ACCs) is higher than in the general population. The coexistence of benign and malignant masses has seldom been documented, leaving open the question of ACC progression from benign forms. We report a comprehensive genetic characterization of three adrenal cortical tumor samples obtained from a familial MEN1 patient, operated for the rapid progression of an initially stable nonfunctional adrenal incidentaloma. Histologically, the tumor consisted of a small ACA contiguous to a large ACC, which subsequently relapsed. Exome sequencing of ACC, ACA and recurrence evidenced a MEN1 loss of heterozygosity (LOH) in ACC but not in ACA, where, however, a second hit driven by alternative mechanisms could not be excluded. The majority of the ACA variants were found to co-occurred in ACC (n = 36/42) and were benign, except for two of unknown significance in KANK1 and REN genes, described as associated with renal cancer. Among variants shared between ACC and its recurrence (n = 69), 11 were Tier III, while 2 affecting TP53 and NF1 genes were pathogenic. Bioinformatic clonal evolution analysis identified one clone − characterized by TP53 and NF1 mutations − absent in ACA but present in ACC and recurrence, as well as 2 clones shared between ACA and ACC but lost in the recurrence. In conclusion, comparative Whole Exome Sequencing (WES) analysis of three adrenal tumors in a MEN1 patient suggests a possible relationship between malignant and benign lesions occurring in MEN1 patients, without, however, demonstrating any causal adenoma-to-carcinoma progression driven by MEN1 LOH. Overall, these data further suggest an increased risk of MEN1 patients to develop adrenocortical malignancy.

The online version contains supplementary material available at 10.1007/s12022-026-09908-0.

## Linked entities

- **Genes:** MEN1 (menin 1) [NCBI Gene 4221], KANK1 (KN motif and ankyrin repeat domains 1) [NCBI Gene 23189], REN (renin) [NCBI Gene 5972], TP53 (tumor protein p53) [NCBI Gene 7157], NF1 (neurofibromin 1) [NCBI Gene 4763]
- **Diseases:** multiple endocrine neoplasia type 1 (MONDO:0007540), adrenal cortical adenoma (MONDO:0003924), adrenal cortical carcinoma (MONDO:0006639)

## Full-text entities

- **Genes:** IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, MAP4K1 (mitogen-activated protein kinase kinase kinase kinase 1) [NCBI Gene 11184] {aka HPK1}, FAM47E (family with sequence similarity 47 member E) [NCBI Gene 100129583], TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MEN1 (menin 1) [NCBI Gene 4221] {aka MEAI, SCG2}, WDR7 (WD repeat domain 7) [NCBI Gene 23335] {aka TRAG}, REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, SF1 (splicing factor 1) [NCBI Gene 7536] {aka BBP, D11S636, MBBP, ZCCHC25, ZFM1, ZNF162}, SATB2 (SATB homeobox 2) [NCBI Gene 23314] {aka C2DELq32q33, DEL2Q32Q33, GLSS}, SLC26A2 (solute carrier family 26 member 2) [NCBI Gene 1836] {aka D5S1708, DTD, DTDST, EDM4, MST153, MSTP157}, KANK1 (KN motif and ankyrin repeat domains 1) [NCBI Gene 23189] {aka ANKRD15, CPSQ2, KANK}, NF1 (neurofibromin 1) [NCBI Gene 4763] {aka NFNS, VRNF, WSS}, ATG12 (autophagy related 12) [NCBI Gene 9140] {aka APG12, APG12L, FBR93, HAPG12}, LCK (LCK proto-oncogene, Src family tyrosine kinase) [NCBI Gene 3932] {aka IMD22, LSK, YT16, p56lck, pp58lck}, GABRB3 (gamma-aminobutyric acid type A receptor subunit beta3) [NCBI Gene 2562] {aka DEE43, ECA5, EIEE43}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, IRF7 (interferon regulatory factor 7) [NCBI Gene 3665] {aka IMD39, IRF-7, IRF-7H, IRF7A, IRF7B, IRF7C}
- **Diseases:** breast cancer (MESH:D001943), hemorrhagic (MESH:D006470), ACC (MESH:D004476), mature B-cell neoplasms (MESH:D016393), premalignant lesion (MESH:D009059), esophageal-stomach cancer (MESH:D013274), lymph node and bone metastases (MESH:D008207), adenoma (MESH:D000236), ovarian cancer (MESH:D010051), tumorigenesis (MESH:D063646), ACA (MESH:D018246), adrenal incidentaloma (MESH:C538238), autosomal dominant disorder (MESH:D030342), liver cancer (MESH:D006528), primary hyperparathyroidism (MESH:D049950), Necrotic (MESH:D009336), adrenal cortical tumor (MESH:D000314), renal cancer (MESH:D007680), Adrenal lesions (MESH:D000307), gastrointestinal neuroendocrine tumor (MESH:D018358), myelodysplastic syndrome (MESH:D009190), soft tissue sarcoma (MESH:D012509), ACA (MESH:D020243), non-small cell lung cancer (MESH:D002289), renal cell carcinoma (MESH:D002292), masses (MESH:C536030), ACCs (MESH:D018268), MEN1 (MESH:D018761), pituitary microadenoma (MESH:D010900), prostate cancer (MESH:D011471), melanoma (MESH:D008545), glioma (MESH:D005910), endometrial cancer (MESH:D016889), prolactin (MESH:C562708), bone pain (MESH:D010146), pancreatic cancer (MESH:D010190), colorectal cancer (MESH:D015179), adenoma-to-carcinoma (MESH:D000230), Tumors (MESH:D009369), lesions of the adrenal cortex (MESH:D000303), adrenocortical lesions (MESH:D000306), head and neck cancer (MESH:D006258), adrenal tumor (MESH:D000310)
- **Chemicals:** nivolumab (MESH:D000077594), EDP (-), cisplatin (MESH:D002945), H&amp;E (MESH:D006371), mitotane (MESH:D008939), capecitabine (MESH:D000069287), temozolomide (MESH:D000077204)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Cys1114Ter, c.376T > G, c.1031 C > G, c.73G > T, c.865G > C, c.1252 C > T, c.1547G > A, Ser344Cys, c.625G > C, Glu209Gln, p.(Asn137Asp), Trp516Ter, c.1154del, c.235 C > T, c.416G > A, Glu125Lys, c.3342T > A, c.373G > A, c.995 C > A, p.(Asp25Tyr), c.4333-1G > C, c.4270-1G > C, p.(Asp289His)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12975836/full.md

---
Source: https://tomesphere.com/paper/PMC12975836